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Abstract—In the reaction of allenylphosphonates with amines/nucleobases, depending on the amine and the allenylphosphonate, either Z- or
E-vinylphosphonate or allylphosphonate as a single isomer with a b-amino functionality was isolated. A simple route to phosphonates with
a b-NH2 group is developed by direct reaction with ammonia. In reactions with adenine, three different modes of reaction, with one of
them involving an unusual cyclisation, are observed. The utility of (enamino)allyl phosphonate products thus obtained in the synthesis of
(enamino)-1,3-butadienes via Horner–Wadsworth–Emmons (HWE) reaction is also demonstrated.
 2006 Elsevier Ltd. All rights reserved.1. Introduction
Allenes serve as potential precursors for a variety of
molecules of industrial and biological importance.1,2 Alle-
nylphosphonates (phosphorylated allenes) 1 constitute
a readily accessible family of allenes that can be used as
versatile building blocks in organic chemistry.3 One of their
simplest reactions is amination leading to vinyl and/or allyl-
phosphonates (2a–b); when aromatic amines are used, imine
type of products (2c) are also possible.4 It should be noted
that the factors governing different modes of reactivity are
not clear, but all of these (2a–c) upon reduction can lead
to b-aminophosphonates that have a wide range of biological
activity.5 Compounds of type 2a are well characterised but
those of type 2b are not. These latter compounds should
be good precursors for Horner–Wadsworth–Emmons reac-
tions. Among several synthetic routes for these b-amino-
phosphonates,5c,6 one using enaminophosphonates is
attractive because of the ease of preparation of the allenyl-
phosphonate precursors. Also, if adenine, guanine, etc., are
utilised as the amine components, it should be possible to
obtain nucleobase-appended phosphonates that could be of
biochemical interest (e.g., chemotherapy).7 The reactive
site in these nucleobases is another aspect on which details
are unclear.0040–4020/$ - see front matter  2006 Elsevier Ltd. All rights reserved.
doi:10.1016/j.tet.2006.08.034In addition to the above, enamines themselves are valuable
intermediates in organic synthesis.8 Unlike the thermo-
dynamically unstable primary and secondary enamines,
enaminophosphonates are relatively stable.9 Thus amination
of phosphorylated allenes constitutes a potential entry to
stable enamines. Nonphosphorylated allenes undergo ami-
nation mainly under catalytic conditions to lead to the allyl-
amines;10 in particular, the phosphine catalysed reaction of
azoles with allenes takes place at the terminal carbon.10d
In the above context and in continuation of our work on
phosphonate/phosphorane chemistry,11 we have explored
the amination reactions of phosphorylated allenes.12 Our
results reveal an interesting array of products, not evident
in earlier reports, in this apparently naive reaction. These
results are reported here.
2. Results and discussion
In this paper, the following results are discussed in the same
order: (i) synthesis and characterisation of (E)-(enamino)-
vinyl phosphonates 4a–b and (enamino)allyl phosphonates
5a–d,13 (ii) an extremely simple and straightforward route
to the stable (Z)-b-enaminophosphonates 6–76f and (iii) firstP
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guanine) connected phosphonates 8–13 as single isomers,14
and the unusual cyclisation product 14 with adenine residue.
These compounds are shown in Chart 1.
Utility of the addition product of 3c with N-methylethanol-
amine in the synthesis of adenyl-substituted phosphonates
and of compounds 5b and 5d in the Horner–Wadsworth–
Emmons (HWE) reaction leading to 1,3-butadienes is dis-
cussed later.
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                  = CH, Y = N   [5b]
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                  = CH, Y = N   [5d]
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6 (X-ray)
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      O     [4b]
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B = 9-adenyl [9] (X-ray)  
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   = cytosinyl  [11] (X-ray)
   = 9-guanyl  [12]
7 (X-ray)
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Chart 1.2.1. Reaction of allenes 3a–b with secondary amines—
formation of (E)-(enamino)vinyl phosphonates 4a–b and
(enamino)allyl phosphonates 5a–d
These reactions were conducted in methyl cyanide at 25 or
70 C (Scheme 1). The yields are summarised in Table 1.
Although it is reported in the literature that there is an equi-
librium between the (enamino)vinyl phosphonate and the
corresponding (enamino)allyl phosphonate as shown in
Scheme 2,3a we did not find any evidence for the thermal con-
version of 4a (Chart 1, see Supplementary data for X-ray
structure) to its (enamino)allyl form or of 5a (Chart 1, see
Supplementary data for X-ray structure) to its (enamino)-
vinyl form. Even in the reaction mixture, only one com-
pound, either 4 or 5, was observed (31P NMR) at 25 C in
both the cases. The amine adds to the central carbon in the re-
actions shown in Scheme 1. In contrast, it is important to note
that phosphine catalysed addition of azoles to activated allenes
takes place at the terminal carbon (Scheme 3).10d The E ste-
reochemistry for 4a observed here is different from Z stereo-
chemistry observed for (Me)(NEt2)C]C(F)[P(O)(OEt)]2.
4b
A preliminary theoretical study at B3LYP/6-31G* level
using Gaussian ’03 program package (see Supplementary
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Scheme 1.Table 1. Details on the reaction of phosphorylated allenes with amines/nucleoside bases
Entry Allenylphosphonate Amine, reaction conditions Products Yield (%)
1 3a Piperidine, CH3CN, rt 4a 100 (quantitative)
2 3a Morpholine, CH3CN, rt 4b 100 (quantitative)
3 3a Pyrazole, CH3CN, 70
C 5a 80
4 3a Imidazole, CH3CN, 70
C 5b 86
5 3b Pyrazole, CH3CN, 70
C 5c 54
6 3b Imidazole, CH3CN, 70
C 5d 62
7 3a Ammonia, CH3CN, rt 6 100 (quantitative)
8 3c Ammonia, CH3CN, rt 7 100 (quantitative)
9 3a Adenine, DMF, K2CO3, rt 8 52
10 3c Adenine, DMF, K2CO3, rt 9 70
11 3c Thymine, DMF, K2CO3, rt 10 65
12 3c Cytosine, DMF, K2CO3, rt 11 56
13 3c Guanine, DMF, K2CO3, rt 12 68
14 3d Adenine, DMF, K2CO3, rt 13+14 44+25
15 3c N-methylethanolamine, CH3CN, rt 16 100 (quantitative)
10154 K. C. Kumara Swamy et al. / Tetrahedron 62 (2006) 10152–10161data for details) for 4a and 5a suggested that enamino(vinyl)
form (type 4) is more stable in the gas phase. However, it
should be pointed out that gas phase stability could be differ-
ent from that of the observed stability in solution/solid state.
The main difference between compounds 4a and 5a is the
presence of a saturated ring in the former and an unsaturated
ring in the latter; to what extent this feature affects the stabil-
ity of the vinyl and allyl forms is still not clear.
2.2. Reaction of allenes 3a and 3c with ammonia—
formation of (Z)-(enamino)vinyl phosphonates 6–7
Compound 6 or 7 (quantitative yields) could be readily ob-
tained after passing dry ammonia into a methyl cyanide
solution of allene 3a or 3c, respectively (Scheme 4). For both
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Scheme 4.of these, the Z form (Fig. 1 for 6 and Supplementary data for
the X-ray structure of 7), and not the E form observed in 4a–
b, is favoured because of intramolecular hydrogen bonding
involving the phosphoryl oxygen. Although intermolecular
hydrogen bonding is also present, formation of hydrogen-
bonded six-membered ring appears to have driven the struc-
ture towards the Z configuration in 6 and 7. Previous reports
have also suggested that the intramolecular hydrogen bond-
ing leads to the Z form, but structural proof was not availa-
ble.6f Our route also offers a viable alternative to the
literature method (cf. Scheme 5) because of the ease of syn-
thesis. The potentially reactive b-NH2 group of 6–7 makes
them attractive precursors for further investigations.6c,6f
2.3. Reaction of allenylphosphonates with nucleobases—
adenyl, thyminyl, cytosinyl and guanyl phosphonates
8–13 and the unusual cyclisation product 14
Reaction of allenes 3a and 3c with adenine in DMF at 25 C
afforded only the E isomer of the expected (enamino)vinyl
phosphonates 8 and 9 (Scheme 6, see Supplementary data
for X-ray structure). Details of the reaction conditions,
yields, etc., are given in Scheme 6 and Table 1. Analogous
reaction of 3c with thymine, cytosine and guanine led to
the (enamino)vinyl phosphonates 10–12 (Scheme 6, see
Supplementary data for the X-ray structures).15 To our
knowledge, this is the first authentic report on the isolation
of nucleobase-appended (enamino)vinyl phosphonates from
the reaction of allenylphosphonates. Column chromato-
graphy was employed to separate the products from the
unreacted allene/nucleobase. The other by-products were
mainly the isomeric alkyne or the b-ketophosphonate
formed due to hydrolysis of the allene.
P
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O3C1
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C4
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N1
Figure 1. A PLATON drawing of 6 showing hydrogen bonding. P–C(6)
1.718(6) A˚. Hydrogen bond parameters: N(1)–H(1)/O(3) 0.92(6), 2.23(5),
2.950(7) A˚, 135(5); N(1)–H(2)/O(30) 0.86(6), 2.34(6), 3.157(7) A˚
160(6); N(1)–H(1)/O(10) [not shown in the picture] 0.92(6), 2.70(6),
3.319(7) A˚, 126(4).
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Scheme 5.
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reaction of adenine with ]CH2 terminal allenes 3a and 3c,
the allylphosphonate 13 (see Supplementary data for X-ray
structure) and the novel cyclised product 14 (Scheme 7,
Fig. 2) are obtained from the reaction of the ]CMe2 termi-
nal allene 3d with adenine. Compounds 13 and 14 could be
readily separated from the same reaction mixture of the
allene 3d with adenine. The reactive centre in each of the
nucleobases used in the present study (except in 14) is
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Scheme 7.similar to that found in analogous reactions with terminal
phosphorylated acetylenes, thus suggesting that they are
the preferred sites of action.7d Under these conditions, tradi-
tional allenes 15a–c did not react with adenine.
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A plausible pathway for the formation of the unusual ring
compound 14 is depicted in Scheme 8.16 Here species A is
the N(7) analogue of compound 13 [which is the N(9) deriv-
ative]. It should be noted that attack from N(7) of adenine is
rather rare. Cyclisation involving the attack of the adenine–
NH2 at phosphorus leading to the seven-membered ring
probably occurs via a pentacoordinated transition state,
and to our knowledge, does not have precedence.
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Figure 2. A PLATON drawing of 14. Hatched lines represent hydrogen
bonds. Selected distances: PN(5) 1.617(2), P–C(24) 1.798(2), N(5)–C(29)
1.315, N(2)–C(25) 1.436(3), N(4)–C(29) 1.374(3) A˚.
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Scheme 9.2.4. Reaction of N-methylethanolamine with 3c—use of
the residual –OH group in the Mitsunobu coupling
to adenine
Since secondary amines like piperidine and morpholine gave
the vinyl phosphonates 4a–b, we were interested in utilising
this feature for inserting functionalised amines. As an exam-
ple, by using N-methylethanolamine, we obtained product
16 in which the –OH group is intact. This residual –OH
group undergoes facile Mitsunobu coupling with adenine
to give the N-alkylated product 17 (Scheme 9), thus offering
adenyl functionality at the u-position of the phosphonate
(see Supplementary data for X-ray structure).
2.5. Horner–Wadsworth–Emmons reaction of 5b and 5d
with aldehydes
It can be noted that compounds 5a–d possess a P–CH2 group
ideally suited for Horner–Wadsworth–Emmons reaction.
Thus we have utilised 5b and 5d for the synthesis of
substituted butadienes 18–19 (Scheme 10). To our knowl-
edge, no other simpler route to such interesting butadienes
with an enamine functionality is available in the literature.
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3. Conclusion
In summary, the amination of allenylphosphonates, includ-
ing those with nucleobases, takes place readily even in the
absence of a transition metal catalyst leading to a single iso-
mer of (enamino)vinyl or (enamino)allyl phosphonate while
the allenes 15a–c remained unreactive towards nitrogen
nucleophiles. Unlike the equilibrium between the vinyl
and allyl forms suggested in previous studies, only one
form in each case was stable in the solution (31P NMR
evidence) as well as the solid state (X-ray). A very simple
route to synthetically valuable b-NH2 substituted phos-
phonates has been reported. New nucleobase-substitutedphosphonates including a novel cyclisation product involv-
ing adenine, that could have potential biological activities,
are highlighted. Utility of the products in HWE reaction as
well as in the synthesis of remotely functionalized phospho-
nates via Mitsunobu N-alkylation is demonstrated.
4. Experimental
4.1. General
Chemicals were purified when required according to standard
procedures.17a All reactions, unless stated otherwise, were
performed in a dry nitrogen atmosphere. 1H, 13C and 31P{H}
NMR spectra were recorded using a 200 or a 400 MHz
spectrometer in CDCl3 (unless stated otherwise) with shifts
referenced to SiMe4 (d¼0) or 85% H3PO4 (d¼0). Infrared
spectra were recorded on an FT/IR spectrometer. Melting
points were determined by using a local hot-stage melting
point apparatus and are uncorrected. Microanalyses were
performed using a CHNS analyser. Mass spectra were re-
corded using a GCMS-QP2010 and LCMS 2010A.
Precursors 5,5-dimethyl-2-propa-1,2-dienyl-[1,3,2]dioxa-
phosphinane 2-oxide (3a) [dP 7.4] and 5,5-dimethyl-2-
(3-methyl-buta-1,2-dienyl)-[1,3,2]dioxaphosphinane 2-oxide
(3b) [dP 8.5] were prepared using a literature procedure;
12a
an analogous procedure was adapted for 4,8-di-tert-butyl-
2,10-dimethyl-6-propa-1,2-dienyl-12H-5,7-dioxa-6-phos-
pha-dibenzo[a,d]cyclooctene 6-oxide (3c) [dP 8.0] and
4,8-di-tert-butyl-2,10-dimethyl-6-(3-methyl-buta-1,2-dienyl)-
12H-5,7-dioxa-6-phospha-dibenzo[a,d]cyclooctene 6-oxide
(3d) [dP 9.9].
12b Compounds propa-1,2-dienyl-benzene
(15a), (3-methyl-buta-1,2-dienyl)-benzene (15b) and 1-propa-
1,2-dienyl-pyrrolidin-2-one (15c) were prepared by known
methods.17b–c
4.1.1. 1-[2-(5,5-Dimethyl-2-oxo-2l5-[1,3,2]dioxaphos-
phinan-2-yl)-1-methyl-vinyl]-piperidine (4a). To a solu-
tion of allenylphosphonate 3a (1.0 mmol) in dry methyl
cyanide (10 mL), the amine (piperidine or morpholine)
(1.0 mmol) was added via syringe at room temperature
and the mixture was stirred for 4 h; the solution was concen-
trated in vacuo (to ca. 2.5 mL) and kept for crystallisation.
Crystals were obtained after 24 h at 25 C. Yield 0.27 g
(100%); colourless needles; mp 74–76 C [Found: C,
57.05; H, 8.69; N, 5.06. C13H24NO3P requires C, 57.13; H,
8.85; N, 5.12]; nmax (KBr) 1576, 1441, 1416, 1236, 1057,
1011 cm1; dH (200 MHz, CDCl3) 4.23 (dd, JH–H¼4.7 Hz,
10157K. C. Kumara Swamy et al. / Tetrahedron 62 (2006) 10152–10161JH–P¼15.7 Hz, 2H, OCHAHB), 4.00 (d, JH–P¼8.8 Hz, 1H,
PCH), 3.72 (dd, JH–H¼4.7 Hz, JH–P¼15.7 Hz, 2H,
OCHAHB), 3.25 (br, 4H, N(CH2CH2CH2CH2CH2–)), 2.29
(d, JH–P¼1.4 Hz, 3H, C(N(CH2)4–)CH3), 1.59 (br, 6H,
C(NCH2CH2CH2CH2CH2–)), 1.14, 0.96 (2s, 6H, C(CH3)2);
dC (100 MHz, CDCl3) 162.0 (d, JC–P¼21.7 Hz), 74.6, 74.5,
73.3 (d, JC–P¼217.4 Hz), 47.2, 32.3 (d, JC–P¼5.1 Hz), 25.2,
24.1, 21.9, 21.4, 18.1 (d, JC–P¼4.8 Hz); dP (80 MHz,
CDCl3) 24.8. X-ray structure was determined for this sample.
4.1.2. 4-[2-(5,5-Dimethyl-2-oxo-2l5-[1,3,2]dioxaphos-
phinan-2-yl)-1-methyl-vinyl]-morpholine (4b). Yield
0.27 g (100%); white solid; mp 100–102 C [Found: C,
52.27; H, 8.01; N, 5.08. C12H22NO4P requires C, 52.31; H,
8.06; N, 5.09]; nmax (KBr) 1584, 1453, 1400, 1233, 1055,
997 cm1; dH (200 MHz, CDCl3) 4.09 (dd, JH–Hw2.0 Hz,
JH–P¼10.8 Hz, 1H, OCHAHB), 4.00 (d, JH–P¼8.8 Hz, 1H,
PCH), 3.63 (m, 6H, N(CH2CH2OCH2CH2–)), 3.13 (t, JH–H¼
5.0 Hz, 4H, N(CH2CH2OCH2CH2–)), 2.20 (d, JH–P¼2.0 Hz,
3H, N(CH2CH2OCH2CH2–)CH3), 1.04, 0.90 (2s, 6H,
C(CH3)2); dC (50 MHz, CDCl3) 162.6 (d, JC–P¼20.5 Hz),
76.7 (d, JC–P¼214.0 Hz), 74.7, 66.2, 46.2, 32.4 (d, JC–P¼
4.4 Hz), 21.9, 21.4, 17.6 (d, JC–P¼3.8 Hz); dP (80 MHz,
CDCl3) 22.7.
4.1.3. 1-[1-(5,5-Dimethyl-2-oxo-2l5-[1,3,2]dioxaphos-
phinan-2-ylmethyl)-vinyl]-1H-pyrazole (5a).To a solution
of allenylphosphonate 3a (1.88 g, 10.0 mmol) in dry methyl
cyanide (20 mL), pyrazole (0.68 g, 10.0 mmol) was added
and the reaction mixture heated under reflux (70 C) for
14 h with continuous stirring. The solvent was removed un-
der reduced pressure and the solid obtained was purified by
column chromatography (silica gel, hexane–ethyl acetate).
The product was crystallised from dichloromethane–hexane
mixture (1:1). Yield 2.02 g (80%); colourless rectangular
plates; mp 79–81 C [Found: C, 51.46; H, 6.76; N, 10.73.
C11H17N2O3P requires C, 51.56; H, 6.69; N, 10.83]; nmax
(KBr) 1649, 1478, 1262, 1053, 1005 cm1; dH (200 MHz,
CDCl3) 7.76 (d, JH–H¼2.0 Hz, 1H, pyrazolyl-H), 7.56 (br
s, 1H, pyrazolyl-H), 6.32 (d, JH–H¼2.0 Hz, 1H, pyrazolyl-
H), 5.36, 5.07 (2d, JH–H¼4.8 Hz, 2H, ]CH2), 3.75–4.02
(m, 4H, OCH2), 3.45 (d, JH–P¼21.3 Hz, 2H, PCH2), 1.04,
0.91 (2s, 6H, C(CH3)2); dC (50 MHz, CDCl3) 142.0, 136.3
(d, JC–P¼10.4 Hz), 127.4, 107.3, 103.8 (d, JC–P¼9.7 Hz),
75.7, 75.6, 32.1 (d, JC–P¼5.5 Hz), 28.2 (d, JC–P¼
133.1 Hz), 21.4, 20.7; dP (80 MHz, CDCl3) 18.0. X-ray
structure was determined for this sample.
4.1.4. 1-[1-(5,5-Dimethyl-2-oxo-2l5-[1,3,2]dioxaphos-
phinan-2-ylmethyl)-vinyl]-1H-imidazole (5b). The proce-
dure was the same as that for 5a using imidazole instead of
pyrazole. Yield 1.58 g (86%); pale yellow solid; mp 69–
71 C [Found: C, 51.56; H, 6.72; N, 10.78. C11H17O3N2P
requires C, 51.56; H, 6.69; N, 10.83]; nmax (KBr) 1647,
1489, 1269, 1059 cm1; dH (400 MHz, CDCl3) 7.78, 7.21,
7.11 (3 br s, 3H, imidazolyl-H), 5.34, 5.22 (2d, JH–H¼5.2 Hz,
2H, C]CH2), 4.26 (dd, JH–H¼4.8 Hz, JH–P¼11.1 Hz, 2H,
OCHAHB), 3.75 (dd, JH–H¼4.8 Hz, JH–P¼12.1 Hz, 2H,
OCHAHB), 3.18 (d, JH–P¼20.0 Hz, 2H, PCH2), 1.07, 0.98
(2s, 6H, C(CH3)2); dC (100 MHz, CDCl3) 135.6, 133.3 (d,
2JC–P¼10.0 Hz), 130.0, 117.4, 108.2 (d, JC–P¼9.7 Hz),
75.5, 75.3, 32.5, 31.0 (d, JC–P¼137.0 Hz), 21.4, 21.2; dP
(80 MHz, CDCl3) 18.3.4.1.5. 1-[1-(5,5-Dimethyl-2-oxo-2l5-[1,3,2]dioxaphos-
phinan-2-ylmethyl)-2-methyl-propenyl]-1H-pyrazole
(5c). This compound was obtained by using 10.5 mmol of the
allene 3b and following the same procedure as that for 5a.
Yield 1.37 g (54%); white solid; mp 102 C [Found: C,
54.80; H, 7.49; N, 9.74. C13H21O3N2P requires C, 54.92;
H, 7.44; N, 9.85]; nmax (KBr) 3108, 1721, 1672, 1643,
1510, 1285, 1065 cm1; dH (400 MHz, CDCl3) 7.47, 7.39,
6.15 (3 br s, 3H, pyrazolyl-H), 3.79–3.73 (m, 2H, OCHAHB),
3.51–3.48 (m, 2H, OCHAHB), 3.17 (d, JH–P¼19.6 Hz, 2H,
PCH2), 1.83 (d, JH–P¼4.0 Hz, 3H, C]C(CH3A)2), 1.48 (d,
JH–P¼5.6 Hz, 3H, C]C(CH3B)2), 0.93, 0.77 (2s, 6H,
C(CH3)2); dC (100 MHz, CDCl3) 139.6, 134.0 (d, JC–P¼
11.6 Hz), 132.3, 123.7 (d, JC–P¼13.0 Hz), 75.7, 75.6, 32.2
(d, JC–P¼6.5 Hz), 27.7 (d, 1JC–P¼131.8 Hz), 21.4, 20.9,
20.4, 20.1; dP (160 MHz, CDCl3) 20.8; LCMS: 285 [M+1]
+.
4.1.6. 1-[1-(5,5-Dimethyl-2-oxo-2l5-[1,3,2]dioxaphos-
phinan-2-ylmethyl)-2-methyl-propenyl]-1H-imidazole
(5d). This compound was obtained by using 10.5 mmol of
the allene 3b and following the same procedure as that for
5a. Yield 1.58 g (62%); light brown solid; mp 78 C [Found:
C, 54.88; H, 7.38; N, 9.84. C13H21O3N2P requires C, 54.92;
H, 7.44; N, 9.85]; nmax (KBr) 3106, 1684, 1489, 1263, 1063,
820 cm1; dH (400 MHz, CDCl3) 7.49, 7.26, 6.95 (3 br s,
3H, imidazolyl-H), 4.15–4.10 (m, 2H, OCHAHB), 3.67–3.60
(m, 2H, OCHAHB), 3.02 (d, JH–P¼21.0 Hz, 2H, PCH2), 1.95
(d, JH–P¼4.6 Hz, 3H, C]C(CH3A)2), 1.54 (d, JH–P¼6.1 Hz,
3H, C]C(CH3B)2), 0.99, 1.02 (2s, 6H, C(CH3)2); dC
(50 MHz, CDCl3) 137.6, 136.4 (d, JC–P¼10.9 Hz), 128.9,
119.3, 119.8, 75.3, 75.1, 32.5 (d, JC–P¼6.0 Hz), 30.1 (d,
JC–P¼135.8 Hz), 21.3, 20.5, 20.0; dP (80 MHz, CDCl3) 21.0.
4.1.7. 2-(5,5-Dimethyl-2-oxo-2l5-[1,3,2]dioxaphos-
phinan-2-yl)-1-methyl-vinylamine (6). To a solution of
allenylphosphonate 3a (1.0 mmol) in 5 mL dry methyl
cyanide, an excess of a saturated solution of ammonia in
dry methyl cyanide (20 mL) was added slowly at 0 C with
continuous stirring. After 15 min the reaction was brought
to room temperature, continued the stirring for about 1 h.
After removal of the solvent under reduced pressure, 3 mL
of dry toluene was added to get the crystals at 0 C after
one day. However, direct passing of ammonia gas to the phos-
phorylated allene in toluene did not give the product.
Yield 0.20 g (100%); colourless needles; mp 82–84 C
[Found: C, 46.80; H, 7.87; N, 6.76. C8H16O3NP requires
C, 46.83; H, 7.86; N, 6.83]; nmax (KBr) 3409, 3322, 3239,
3202, 1647, 1576, 1429, 1219, 1059 cm1; dH (400 MHz,
CDCl3) 6.00 (br s, 2H, NH2), 4.24–4.28 (dd, JH–Hw2.3 Hz,
JH–Pw9.4 Hz, 2H, OCH2), 3.66–3.78 (m, 3H, OCH2+PCH),
1.93 (s, 3H, CH3), 1.17, 0.88 (2s, 6H, C(CH3)2); dC (50 MHz,
CDCl3) 163.0 (d, JC–P¼6.1 Hz), 74.2, 74.1, 69.9 (d, JC–P¼
201.3 Hz), 31.8 (d, JC–P¼5.0 Hz), 23.9 (d, JC–P¼21.5 Hz),
21.7, 21.0; dP (160 MHz, CDCl3) 23.2. X-ray structure was
determined for this sample.
4.1.8. 2-(4,8-Di-tert-butyl-2,10-dimethyl-6-oxo-12H-5,7-
dioxa-6l5-phospha-dibenzo[a,d]cycloocten-6-yl)-1-
methyl-vinylamine (7). The procedure was the same as that
for 6 using 3c and the same molar quantities. Yield 0.44 g
(100%); colourless rectangular blocks; mp 130–132 C
[Found: C, 70.63; H, 8.12; N, 3.28. C26H36O3NP requires
10158 K. C. Kumara Swamy et al. / Tetrahedron 62 (2006) 10152–10161C, 70.72; H, 8.22; N, 3.19]; nmax (KBr) 3420, 3326, 3239,
3204, 1640, 1582, 1439, 1217, 1138 cm1; dH (400 MHz,
CDCl3) 6.98–7.06 (2 br s, 4H, Ar-H), 4.40 (br s, 1H,
ArCHAHX), 4.08 (d, JH–P¼14.8 Hz, 1H, PCH), 3.79(d,
JH–H¼13.6 Hz, 1H, ArCHAHX), 2.27 (s, 6H, ArCH3), 1.97,
(s, 3H, CH3), 1.38 (s, 18H, t-Bu-H); dC (50 MHz, CDCl3)
160.7 (d, JC–P¼6.0 Hz), 147.2, 147.0, 140.8, 140.6, 133.5,
131.6, 129.4, 126.9, 73.7 (d, JC–P¼208.6 Hz), 36.1, 34.8,
30.8, 24.3 (d, JC–P¼23.0 Hz), 21.0; dP (160 MHz, CDCl3)
17.4; GC–MS: 441 [M]+. X-ray structure was determined
for this sample.
4.2. Synthesis of nucleobase-appended phosphonates
8–14: representative procedure for 9
Method A: A mixture of adenine (0.191 g, 1.4 mmol), potas-
sium tert-butoxide (0.157 g, 1.4 mmol) and catalytic amount
of 18-crown–6 in dry methyl cyanide (80 mL) was stirred at
room temperature for 30 min. Phosphorylated allene 3c
(0.191 g, 1.2 mmol) was then added all at once under a nitro-
gen atmosphere and the mixture stirred for overnight. The
insolubles were filtered off and the solvent from the filtrate
removed under reduced pressure. The residue was chromato-
graphed on a silica gel column using ethyl acetate–hexane
mixture as the eluent.
Method B: A mixture of adenine (0.191 g, 1.4 mmol) and po-
tassium carbonate (0.195 g, 1.4 mmol) in dry DMF (70 mL)
was stirred at room temperature for 15 min. Phosphorylated
allene 3c (0.50 g, 1.2 mmol) was then added all at once un-
der a nitrogen atmosphere with stirring. Progress of the reac-
tion was monitored by TLC. The solid was filtered off and
the solvent was removed by vacuum distillation.
The residue was chromatographed on a silica gel with ethyl
acetate–hexane mixture.
Method B gave better yields than method A (using 3c); this
is what is given below and in Table 1. Crystals (compounds
9, 10, 11 and 13) suitable for X-ray crystallography were
obtained from methanol–methyl cyanide (w1:2) mixture.
4.2.1. 9-[2-(5,5-Dimethyl-2-oxo-2l5-[1,3,2]dioxaphos-
phinan-2-yl)-1-methyl-vinyl]-9H-purin-6-ylamine (8).
Yield 0.20 g (52%); white solid; mp 270 C [Found: C,
48.24; H, 5.51; N, 21.60. C13H18O3N5P requires C, 48.30;
H, 5.61; N, 21.66]; nmax (KBr) 3304, 3152, 1671, 1642,
1605, 1564, 1476, 1238, 1057 cm1; dH (400 MHz, DMSO-
d6) 8.40, 8.25 (2s, 2H, adenyl-H), 8.09 (br s, 2H, NH2),
7.15 (d, JH–P¼12.0 Hz, 1H, PCH), 3.98–4.11 (multiplet,
4H, OCH2), 2.72 (s, 3H, CH3), 1.21, 0.96 (2s, 6H,
C(CH3)2); Solubility was too low to record the
13C NMR;
dP (160 MHz, DMSO-d6) 12.1. Crystals were obtained from
dimethyl sulfoxide (not suitable for X-ray crystallography).
4.2.2. 9-[2-(4,8-Di-tert-butyl-2,10-dimethyl-6-oxo-12H-
5,7-dioxa-6l5-phospha-dibenzo[a,d]cycloocten-6-yl)-
1-methyl-vinyl]-9H-purin-6-ylamine (9). Yield 0.47 g
(70%); colourless needles; mp 248–250 C [Found: C,
66.58; H, 6.85; N, 12.65. C31H38O3N5P requires C, 66.53;
H, 6.84; N, 12.52]; nmax (KBr) 3308, 3144, 1682, 1605,
1561, 1458, 1213, 1136 cm1; dH (400 MHz, CDCl3) 8.42
and 8.10 (2s, 2H, adenyl-H), 7.72 (d, JH–P¼12.0 Hz, 1H,
PCH), 7.05 (s, 4H, Ar-H), 5.80 (br s, 2H, NH2), 3.90–4.10(br s, 2H, ArCH2), 2.94 (d, JH–P¼2.9 Hz, 3H, CH3), 2.29
(s, 6H, ArCH3), 1.38 (s, 18H, t-Bu-H); dC (50 MHz,
CDCl3) 156.0, 153.7, 150.6, 147.5 (d, JC–P¼22.5 Hz),
146.1, 140.7, 140.6, 138.1, 134.4, 131.8, 129.5, 127.3,
120.8, 107.2 (d, JC–P¼209.8 Hz), 35.6, 34.8, 30.9, 21.0,
18.6; dP (160 MHz, CDCl3) 10.3. X-ray structure was deter-
mined for this sample.
4.2.3. 1-[2-(4,8-Di-tert-butyl-2,10-dimethyl-6-oxo-12H-
5,7-dioxa-6l5-phospha-dibenzo[a,d]cycloocten-6-yl)-1-
methyl-vinyl]-5-methyl-1H-pyrimidine-2,4-dione (10).
Yield 0.42 g (65%); colourless needles; mp 220 C [Found:
C, 67.53; H, 7.12; N, 5.19. C31H39O5N2P requires C, 67.62;
H, 7.14; N, 5.10]; nmax (KBr) 3567 (br), 3206, 3075, 1699,
1458, 1260, 931 cm1; dH (400 MHz, CDCl3) 8.20 (br s,
1H, thyminyl-NH), 7.06 (br s, 4H, Ar-H), 6.91 (s, 1H,
thyminyl-H), 6.01 (d, JH–P¼10.4 Hz, 1H, PCH), 4.06 (br s,
2H, ArCH2), 2.64 (d, JH–P¼3.2 Hz, 3H, CH3), 2.29 (s, 6H,
ArCH3), 1.97 (s, 3H, thyminyl-CH3), 1.40 (s, 18H, t-Bu-
H); dC (50 MHz, CDCl3) 163.9, 148.7, 140.6, 134.8,
138.6, 131.8, 129.5, 127.5, 111.7, 115.9 (d, JC–P¼
202.5 Hz), 35.3, 34.9, 30.9, 29.7, 19.9; dP (80 MHz,
CDCl3) 6.1. X-ray structure was determined for this sample.
4.2.4. 4-Amino-1-[2-(4,8-di-tert-butyl-2,10-dimethyl-6-
oxo-12H-5,7-dioxa-6l5-phospha-dibenzo[a,d]cycloocten-
6-yl)-1-methyl-vinyl]-1H-pyrimidin-2-one (11). Yield
0.36 g (56%); colourless thick rectangular blocks; mp
200–205 C [Found: C, 67.15; H, 7.15; N, 7.85.
C30H38O4N3P requires C, 67.26; H, 7.15; N, 7.85]; nmax
(KBr) 3370, 1651, 1508, 1385, 1211 cm1; dH (400 MHz,
CDCl3: DMSO-d6) 7.20 (d, JH–P¼10.0 Hz, 1H, PCH), 7.09
(s, 4H, Ar-H), 6.06 (d, JH–H¼6.6 Hz, 1H, cytosinyl-H),
5.82 (d, JH–H¼6.4 Hz, 1H, cytosinyl-H), 4.07 (br s, 2H,
ArCH2), 2.63 (s, 3H, CH3), 2.30 (s, 6H, ArCH3), 1.40 (s,
18H, t-Bu-H); 13C NMR spectrum was not clear due to lower
solubility; dP (160 MHz, CDCl3) 8.1. X-ray structure was
determined for this sample.
4.2.5. 2-Amino-9-[2-(4,8-di-tert-butyl-2,10-dimethyl-6-
oxo-12H-5,7-dioxa-6l5-phospha-dibenzo[a,d]cycloocten-
6-yl)-1-methyl-vinyl]-1,9-dihydro-purin-6-one (12).Yield
0.46 g (68%); white solid; mp 268–274 C [Found: C, 64.68;
H, 6.63; N, 12.17. C31H38O4N5P requires C, 64.68; H, 6.65;
N, 12.17]; nmax (KBr) 3393, 3308, 3196, 1703, 1640, 1599,
1211 cm1; dH (400 MHz, CDCl3) 12.30 (br s, 2H, NH2),
7.90 (s, 1H, guanyl-H), 7.50 (d, JH–P¼19.5 Hz, 1H, PCH),
7.06 (br s, 4H, Ar-H), 6.50 (br s, 1H, NH), 4.07 (br s, 2H,
ArCH2), 2.86 (d, JH–P¼3.9 Hz, 3H, CH3), 2.29 (s, 6H,
ArCH3), 1.29 (s, 18H, t-Bu-H); dC (100 MHz, DMSO-d6)
157.0, 154.3, 151.8, 149.3 (d, JC–P¼22.0 Hz), 145.6,
140.9, 136.0, 134.5, 132.9, 129.7, 127.5, 118.6, 103.8 (d,
JC–P¼202.0 Hz), 34.9, 34.2, 31.2, 21.0, 18.6 (d, JC–P¼
3.7 Hz); dP (160 MHz, CDCl3) 10.0.
4.2.6. 9-[1-(4,8-Di-tert-butyl-2,10-dimethyl-6-oxo-12H-
5,7-dioxa-6l5-phospha-dibenzo[a,d]cycloocten-6-yl-
methyl)-2-methyl-propenyl]-9H-purin-6-ylamine (13).
CH3CN and 3-tert-butyl-5-[3-tert-butyl-5-(9-isopropyl-
idene-7-oxo-5,7,8,9-tetrahydro-2,3,5,6,9a-pentaaza-7l5-
phospha-benzo[c,d]azulen-7-yloxy)-2-methyl-benzyl]-4-
methyl-phenol (14). Two products 13 and 14 were obtained
in the reaction of 3d with adenine following the same
10159K. C. Kumara Swamy et al. / Tetrahedron 62 (2006) 10152–10161procedure as that for 9 using the same molar quantities. The
reaction mixture showed two peaks at d 18.8 (ca. 80%) and
19.3 (ca. 20%) in the 31P NMR.
Compound 13: Yield 0.31 g (44%); colourless thin plates;
mp 180–182 C [Found (after drying): C, 67.33; H, 7.26;
N, 11.86. C33H42O3N5P requires C, 67.44; H, 7.20; N,
11.92]; nmax (KBr) 3221, 3113, 3044, 1630, 1588, 1560,
1431, 1174 cm1; dH (400 MHz, CDCl3) 8.35 and 7.93
(2s, 2H, adenyl-H), 6.99 and 6.98 (2s, 4H, Ar-H), 5.58 (br
s, 2H, NH2), 3.90 (d and a broad signal, JH–C–P¼20.8 Hz,
3H, PCH2 merged with peak due to 1H of ArCHAHB), 3.50
(br, 1H, ArCH2), 2.24 (s, 6H, ArCH3), 2.14 (d, JH–P¼
3.5 Hz, 3H, C(CH3A)2), 1.64 (s, 3H, C(CH3B)2), 1.25 (s,
18H, t-Bu-H); dC (100 MHz, CDCl3) 155.5, 153.4, 150.1,
144.6, 144.5, 141.8, 140.9, 138.0, 137.8, 135.0, 132.8,
129.0, 127.6, 119.3, 119.1, 119.0, 34.7, 34.3, 31.3 (d, JC–P¼
146.6 Hz), 30.8, 21.2, 20.9, 20.3, 20.2; dP (160 MHz, CDCl3)
18.8. X-ray structure was determined for this sample.
Compound 14: Yield 0.17 g (25%); colourless diamond-like
crystals; mp 196–198 C [Found: C, 67.48; H, 7.22; N,
11.96. C33H42O3N5P requires C, 67.44; H, 7.20; N, 11.92];
nmax (KBr) 3335, 3177, 1669, 1595, 1456, 1238,
1196 cm1; dH (400 MHz, CDCl3) 8.01 and 7.93 (2s, 2H,
adenyl-H), 7.26, 7.04, 6.93 (3s, 4H, Ar-H), 6.72, 6.48
(2 br s, 2H, NH+OH), 4.90 (br s, 1H, ArCHAHX), 3.67 (d,
JH–P¼21.2 Hz, 2H, PCH), 3.20 (br s, 1H, ArCHAHX), 2.27
and 2.16 (2s, 6H, ArCH3), 2.02 (d, JH–P¼4.8 Hz, 3H,
]C(CH3A)2), 1.83 (d, JH–P¼6.0 Hz, 3H, ]C(CH3B)2),
1.41, 1.20 (2s, 18H, t-Bu-H); dC (100 MHz, CDCl3) 155.6,
145.6, 141.6, 135.2, 132.8, 128.0, 127.6, 126.3, 119.0,
34.8, 34.6 (d, JC–P¼167.3 Hz), 34.5, 31.5, 29.8, 21.2, 21.0,
20.9; dP (160 MHz, CDCl3) 19.2. X-ray structure was deter-
mined for this sample.
4.2.7. 2-{[2-(4,8-Di-tert-butyl-2,10-dimethyl-6-oxo-12H-
5,7-dioxa-6l5-phospha-dibenzo[a,d]cycloocten-6-yl)-1-
methyl-vinyl]-methyl-amino}-ethanol (16). The procedure
is similar to that of 4a using the same molar quantities. Yield
0.49 g (100%); white solid; mp 198–202 C [Found: C,
69.76; H, 8.19; N, 2.82. C29H42O4NP requires C, 69.71; H,
8.21; N, 2.80]; nmax (KBr) 3457, 1570, 1456, 1238, 1132,
1032 cm1; dH (400 MHz, CDCl3) 7.01 (s, 4H, Ar-H),
4.30 (d, JH–P¼8.8 Hz, 1H, PCH), 3.96 (br s, 2H, ArCH2),
3.73 (t, JH–H¼7.1 Hz, 2H, CH2OH), 3.42 (t, JH–H¼7.1 Hz,
2H, NCH2), 2.95 (s, 3H, CH3), 2.44 (s, 3H, NCH3), 2.27
(s, 6H, ArCH3), 1.75 (br s, 1H, OH), 1.39 (s, 18H, t-Bu-
H); dC (50 MHz, CDCl3) 160.3 (d, JC–P¼23.5 Hz), 146.5,
140.8, 134.5, 133.5, 132.3, 129.3, 127.6, 126.9, 82.5 (d,
JC–P¼226.0 Hz), 64.1, 60.1, 53.6, 35.7, 34.8, 30.8, 21.0,
18.2; dP (160 MHz, CDCl3) 19.2.
4.2.8. 9-(2-{[2-(4,8-Di-tert-butyl-2,10-dimethyl-6-oxo-
12H-5,7-dioxa-6l5-phospha-dibenzo[a,d]cycloocten-6-
yl)-1-methyl-vinyl]-methyl-amino}-ethyl)-9H-purin-6-
ylamine (17). To a stirred solution of 16 (0.632 g,
1.05 mmol), triphenylphosphine (0.332 g, 1.27 mmol) and
adenine (0.142 g, 1.05 mmol) in dry THF (25 mL) at room
temperature was added diethylazodicarboxylate dropwise
(0.256 g, 1.27 mmol). The solution was then stirred at
room temperature for 6 h, after which the volatile compo-
nents were removed under reduced pressure and the residuewas purified by chromatography (silica gel, in hexane–ethyl
acetate) to give the pure product as a white solid. Crystals
(17$2MeOH) were obtained after 48 h at 25 C from meth-
anol. Yield 0.37 g (50%); colourless plates; mp 248 C
[Found (after drying): C, 66.25; H, 7.34; N, 13.40.
C34H45O3N6P requires C, 66.21; H, 7.35; N, 13.36]; nmax
(KBr) 3459, 3297, 3129, 1649, 1574, 1439, 1236, 1128,
1026 cm1; dH (400 MHz, CDCl3) 8.37 and 7.63 (2s, 2H,
adenyl-H), 7.02 (br s, 4H, Ar-H), 5.72 (br s, 2H, NH2),
4.32 (br s, 3H, CH2+ArCHAHX), 3.99 (br s, 1H, ArCHAHX),
3.74 (br s, 2H, NCH2), 3.57 (d, JH–P¼23.3 Hz, 1H, PCH),
2.71 (s, 3H, CH3), 2.35 (s, 3H, NCH3), 2.26 (s, 6H,
ArCH3), 1.26–1.43 (multiplet, 18H, t-Bu-H); dC
(100 MHz, CDCl3) 159.0 (d, JC–P¼23.0 Hz), 155.7, 153.2,
149.9, 140.7, 140.4, 133.7, 132.3, 129.2, 127.8, 127.0,
111.6, 78.9 (d, JC–P¼231.0 Hz), 50.9, 41.4, 38.9, 34.8,
31.1, 30.8, 29.5, 21.0; dP (160 MHz, CDCl3) d 18.3;
LCMS: 617 [M]+ (after the loss of methanol solvent).
X-ray structure was determined on this sample.
4.2.9. 1-[2-Methyl-1-(2-p-tolyl-vinyl)-propenyl]-1H-imid-
azole (18). To a suspension of sodium hydride (0.12 g,
4.8 mmol) in THF (10 mL), phosphonate 5b (0.32 g,
1.2 mmol) in THF (20 mL) was added at 0 C and the
mixture stirred for 15 min. Then anisaldehyde (0.17 g,
1.2 mmol) in THF (10 mL) was added slowly (5 min), the
mixture stirred for 4 h, quenched with water (20 mL) and ex-
tracted with ether (320 mL). The combined organic layer
was washed with water, saturated brine solution, dried
(Na2SO4) and the solvent evaporated to afford an oily mate-
rial. This was purified by silica gel column chromatography
using hexane–ethyl acetate mixture. Yield 0.23 g (86%);
pale yellow liquid [Found: C, 80.52; H, 7.65; N, 11.68.
C16H18N2 requires C, 80.63; H, 7.61; N, 11.75]; nmax
(neat) 1709, 1640, 1609, 1510, 1248 cm1; dH (200 MHz,
CDCl3) 7.45, 7.21 (2s, 2H, imidazolyl-H), 7.19 (s, 2H,
Ar-H), 7.13 (d, JH–H¼15.7 Hz, 1H, CHA]CHB), 7.08 (d,
JH–H¼7.8 Hz, 2H, Ar-H), 6.86 (s, 1H, imidazolyl-H), 5.78
(d, JH–H¼15.7 Hz, 1H, CHA]CHB), 2.30 (s, 3H, ArCH3),
2.05 (s, 3H, C]C(CH3A)2), 1.57 (s, 3H, C]C(CH3B)2);
dC (50 MHz, CDCl3) 139.0, 134.4, 133.9, 130.3, 129.4,
129.1, 128.6, 126.5, 122.1, 120.5, 21.2, 20.63, 19.7;
LCMS: 239 [M+1]+.
4.2.10. 1-[3-(4-Methoxy-phenyl)-1-methylene-allyl]-1H-
imidazole (19). The procedure was the same as that for 18
by starting with 5d and using the same molar quantities.
Yield 0.23 g (80%); pale yellow liquid [Found: C, 74.23;
H, 6.21; N, 12.23. C16H18ON2 requires C, 74.31; H, 6.24;
N, 12.36]; nmax (neat) 3119, 1740, 1682, 1603, 1512,
1254 cm1; dH (200 MHz, CDCl3) 7.68 (s, 1H, imidazolyl-
H), 7.33 (d, JH–H¼8.8 Hz, 2H, Ar-H), 7.15 (s, 1H, imid-
azolyl-H), 7.10 (d, JH–H¼2.0 Hz, 1H, imidazolyl-H), 6.87
(d, JH–H¼8.8 Hz, 2H, Ar-H), 6.73 (d, JH–H¼15.6 Hz, 1H,
CHA]CHB), 6.49 (d, JH–H¼15.6 Hz, 1H, CHA]CHB),
5.26, 5.17 (2s, 2H, C]CH2), 3.82 (s, 3H, OCH3); dC
(50 MHz, CDCl3) 160.3, 142.0, 137.0, 132.6, 129.3, 128.4,
122.1, 119.6, 114.4, 109.9, 55.4; LCMS: 227 [M+1]+
(another peak at m/e 385 probably due to dimer minus imi-
dazole was seen).
X-ray crystallography: Single crystal X-ray data were
collected on an Enraf-Nonius MACH3 or on a Bruker
10160 K. C. Kumara Swamy et al. / Tetrahedron 62 (2006) 10152–10161AXS-SMART diffractometer, using Mo Ka (l¼0.71073 A˚)
radiation. The structures were solved by direct methods and
refined by full-matrix least squares method using standard
procedures.18 Absorption corrections were done using
SADABS program, wherever applicable. In some cases,
the terminal carbon atoms of the tert-butyl groups showed
high thermals and hence were refined using a suitable disor-
der model. All nonhydrogen atoms were refined anisotropi-
cally; hydrogen atoms were fixed by geometry or located by
a Difference Fourier and refined isotropically. Crystal data
are available as Supplementary data as well as CIF files.
CCDC reference numbers are 605830–605839.
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